SCHEMBL4476204

SCHEMBL4476204

CCCCN=CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4255843 0.92
SCHEMBL13302530 0.92
SCHEMBL2492904 0.92
SCHEMBL2660180 0.89
SCHEMBL10431397 0.89 MEN1 (0.46)
SCHEMBL22926500 0.89 MEN1 (0.46)
SCHEMBL14437434 0.89
SCHEMBL10737278 0.81
SCHEMBL17887834 0.81
Hydrochloric Acid SCHEMBL10435939 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3739785-B2 2006-01-25 JP claimed
EP-1332150-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF Chattopadhyaya, Jyoti (SE) 2003-08-06 EP claimed
WO-2002038578-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF CHATTOPADHYAYA JYOTI (SE) 2002-05-16 WO claimed
EP-0637965-A4 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. GILEAD SCIENCES INC (US) 1996-01-24 EP claimed
EP-0637965-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1995-02-15 EP claimed
WO-1993010820-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1993-06-10 WO claimed
EP-2054085-A2 NANOPARTICLE NUCLEIC ACID BONDING COMPOUND CONJUGATES FORMING I-MOTIFS Roche Diagnostics GmbH (DE) 2009-05-06 EP disclosed
WO-2008017507-A2 NANOPARTICLE NUCLEIC ACID BONDING COMPOUND CONJUGATES FORMING I-MOTIFS ROCHE DIAGNOSTICS GMBH (DE) 2008-02-14 WO disclosed
EP-1301523-A1 N8 - AND C8 -LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION Roche Diagnostics GmbH (DE) 2003-04-16 EP disclosed
EP-1214331-A2 2-AZAPURINE COMPOUNDS AND THEIR USE Roche Diagnostics GmbH (DE) 2002-06-19 EP disclosed
WO-2001072764-A1 N?8- AND C8¿-LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 WO disclosed
WO-2001016149-A2 2-AZAPURINE COMPOUNDS AND THEIR USE ROCHE DIAGNOSTICS GMBH (DE) 2001-03-08 WO disclosed
WO-1998041523-A1 PROCESS FOR PREPARING DIBENZO-1-CARBOXAMIDO-1,4-AZABICYCLO(3.2.1.) OCTANES NEUROGEN CORPORATION (US) 1998-09-24 WO disclosed
WO-1997032877-A1 PROCESS FOR PREPARING DIBENZO-1-CARBOXAMIDO-1,4-AZABICYCLO[3.2.1]OCTANES NEUROGEN CORPORATION (US) 1997-09-12 WO disclosed
EP-0472526-A4 5-AMINOCARBONYL-5H-DIBENZO A,D)CYCLOHEPTEN-5,10-IMINES FOR TREATMENT OF EPILEPSY AND COCAINE ADDICTION US HEALTH (US) 1992-05-20 EP disclosed
EP-0472526-A1 5-AMINOCARBONYL-5H-DIBENZO a,d]CYCLOHEPTEN-5,10-IMINES FOR TREATMENT OF EPILEPSY AND COCAINE ADDICTION. US HEALTH (US) 1992-03-04 EP disclosed
WO-1990013297-A1 5-AMINOCARBONYL-5H-DIBENZO[a,d]CYCLOHEPTEN-5,10-IMINES FOR TREATMENT OF EPILEPSY AND COCAINE ADDICTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1990-11-15 WO disclosed
US-4238617-A FROM HYDRAZINE, AN AMINE AND A NITRILE ROHM AND HAAS COMPANY (US) 1980-12-09 US disclosed